Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Frits van Rhee; Jean François Rossi; David Simpson; Alexander Fosså; Angela Dispenzieri; John Kuruvilla; Yeow Tee Goh; Seok Goo Cho; Marcelo Capra; Ting Liu; Corey Casper; James Cavet; Raymond S. Wong

doi:10.1111/bjh.17177

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Frits van Rhee
, Jean François Rossi
, David Simpson
, Alexander Fosså
, Angela Dispenzieri
, John Kuruvilla
, Yeow Tee Goh
, Seok Goo Cho
, Marcelo Capra
, Ting Liu
, Corey Casper
, James Cavet
, Raymond S. Wong

Department of Internal Medicine

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	e28-e31
Journal	British Journal of Haematology
Volume	192
Issue number	1
DOIs	https://doi.org/10.1111/bjh.17177
State	Published - Jan 2021

Bibliographical note

Funding Information:
Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May–3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research & Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd.

Funding Information:
Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May?3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research & Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd.

Funding Information:
Frits van Rhee reports receiving research support from Janssen Pharmaceuticals and consultant fees from EUSA Pharma. James Cavet reports receiving research funding, speaker fees and conference support from Janssen/Johnson & Johnson (J&J) and serving on an advisory board for EUSA Pharma. Angela Dispenzieri reports receiving research funding from Alnylam, Celgene, Pfizer and Takeda, and serving on advisory boards for Akcea, Intellia and Janssen. Jean‐François Rossi is the co‐founder of E‐Sana and reports having served on advisory boards for EUSA Pharma, LEO Pharma and Petrovax Pharm. John Kuruvilla reports having received honoraria and research funding from Janssen. Raymond S. Wong reports having received research funding from and served on an advisory board for Janssen/J&J, and speaker fees and conference support from EUSA Pharma and Janssen/J&J. The other authors have no conflicts of interest to disclose.

Keywords

multicentric Castleman disease
siltuximab

Access to Document

10.1111/bjh.17177

Cite this

@article{ed0f70f823ee4e7289b87e7486c5bc4f,

title = "Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab",

keywords = "multicentric Castleman disease, siltuximab",

author = "\{van Rhee\}, Frits and Rossi, \{Jean Fran{\c c}ois\} and David Simpson and Alexander Foss{\aa} and Angela Dispenzieri and John Kuruvilla and Goh, \{Yeow Tee\} and Cho, \{Seok Goo\} and Marcelo Capra and Ting Liu and Corey Casper and James Cavet and Wong, \{Raymond S.\}",

note = "Funding Information: Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May–3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research \& Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd. Funding Information: Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May?3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research \& Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd. Funding Information: Frits van Rhee reports receiving research support from Janssen Pharmaceuticals and consultant fees from EUSA Pharma. James Cavet reports receiving research funding, speaker fees and conference support from Janssen/Johnson \& Johnson (J\&J) and serving on an advisory board for EUSA Pharma. Angela Dispenzieri reports receiving research funding from Alnylam, Celgene, Pfizer and Takeda, and serving on advisory boards for Akcea, Intellia and Janssen. Jean‐Fran{\c c}ois Rossi is the co‐founder of E‐Sana and reports having served on advisory boards for EUSA Pharma, LEO Pharma and Petrovax Pharm. John Kuruvilla reports having received honoraria and research funding from Janssen. Raymond S. Wong reports having received research funding from and served on an advisory board for Janssen/J\&J, and speaker fees and conference support from EUSA Pharma and Janssen/J\&J. The other authors have no conflicts of interest to disclose. ",

year = "2021",

month = jan,

doi = "10.1111/bjh.17177",

language = "English",

volume = "192",

pages = "e28--e31",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

AU - van Rhee, Frits

AU - Rossi, Jean François

AU - Simpson, David

AU - Fosså, Alexander

AU - Dispenzieri, Angela

AU - Kuruvilla, John

AU - Goh, Yeow Tee

AU - Cho, Seok Goo

AU - Capra, Marcelo

AU - Liu, Ting

AU - Casper, Corey

AU - Cavet, James

AU - Wong, Raymond S.

N1 - Funding Information: Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May–3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research & Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd. Funding Information: Presented in abstract form at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), 30 May?3 June 2014, Chicago, IL, USA. This study was sponsored by Janssen Research & Development. The medical writing support was provided by Rory Elsome, BSc, was funded by EUSA Pharma (UK) Ltd. Funding Information: Frits van Rhee reports receiving research support from Janssen Pharmaceuticals and consultant fees from EUSA Pharma. James Cavet reports receiving research funding, speaker fees and conference support from Janssen/Johnson & Johnson (J&J) and serving on an advisory board for EUSA Pharma. Angela Dispenzieri reports receiving research funding from Alnylam, Celgene, Pfizer and Takeda, and serving on advisory boards for Akcea, Intellia and Janssen. Jean‐François Rossi is the co‐founder of E‐Sana and reports having served on advisory boards for EUSA Pharma, LEO Pharma and Petrovax Pharm. John Kuruvilla reports having received honoraria and research funding from Janssen. Raymond S. Wong reports having received research funding from and served on an advisory board for Janssen/J&J, and speaker fees and conference support from EUSA Pharma and Janssen/J&J. The other authors have no conflicts of interest to disclose.

PY - 2021/1

Y1 - 2021/1

KW - multicentric Castleman disease

KW - siltuximab

UR - https://www.scopus.com/pages/publications/85094660493

U2 - 10.1111/bjh.17177

DO - 10.1111/bjh.17177

M3 - Letter

C2 - 33128769

AN - SCOPUS:85094660493

SN - 0007-1048

VL - 192

SP - e28-e31

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this